• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Guardant Health Inc.

    11/13/24 7:34:17 PM ET
    $GH
    Medical Specialities
    Health Care
    Get the next $GH alert in real time by email
    SC 13G 1 form_sc13g-guardant.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

    Guardant Health, Inc.
    (Name of Issuer)

    Common Stock, par value $0.00001 per share
    (Title of Class of Securities)

    40131M109
    (CUSIP Number)

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [X]  Rule 13d-1(b)

    [_]  Rule 13d-1(c)

    [_]  Rule 13d-1(d)

    __________
    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No.
    40131M109
     
     
     
     
     
    1.
    NAME OF REPORTING PERSONS
     
     
     
     
     
    Cadian Capital Management, LP
     
     
     
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
     (a)  [_]
     
     
     (b)  [_]
     
     
     
     
    3.
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     
     
     
    5.
    SOLE VOTING POWER
     
     
     
     
     
    0
     
     
     
     
    6.
    SHARED VOTING POWER
     
     
     
     
     
    7,007,974 (1)
     
     
     
     
    7.
    SOLE DISPOSITIVE POWER
     
     
     
     
     
    0
     
     
     
     
    8.
    SHARED DISPOSITIVE POWER
     
     
     
     
     
    7,007,974 (1)
     
     
     
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
    7,007,974 (1)
     
     
     
     
    10.
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
     [_]
     
     
     
     
     
     
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
    5.7% (2)
     
     
     
     
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IA, PN
     

    (1) Includes 77,500 shares of Common Stock of Guardant Health, Inc. (the “Issuer”) underlying options.
    (2) Based on 123,554,612 shares of Common Stock of the Issuer outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 6, 2024.



    CUSIP No.
    40131M109
     
     
     
     
     
    1.
    NAME OF REPORTING PERSONS
     
     
     
     
     
    Cadian Capital Management GP, LLC
     
     
     
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
     (a)  [_]
     
     
     (b)  [_]
     
     
     
     
    3.
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     
     
     
    5.
    SOLE VOTING POWER
     
     
     
     
     
    0
     
     
     
     
    6.
    SHARED VOTING POWER
     
     
     
     
     
    7,007,974 (1)
     
     
     
     
    7.
    SOLE DISPOSITIVE POWER
     
     
     
     
     
    0
     
     
     
     
    8.
    SHARED DISPOSITIVE POWER
     
     
     
     
     
    7,007,974 (1)
     
     
     
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
    7,007,974 (1)
     
     
     
     
    10.
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
     [_]
     
     
     
     
     
     
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
    5.7% (2)
     
     
     
     
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    OO, HC
     
     
    (1) Includes 77,500 shares of Common Stock of the Issuer underlying options.
    (2) Based on 123,554,612 shares of Common Stock of the Issuer outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 6, 2024.



    CUSIP No.
    40131M109
     
     
     
     
     
    1.
    NAME OF REPORTING PERSONS
     
     
     
     
     
    Eric Bannasch
     
     
     
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
     (a)  [_]
     
     
     (b)  [_]
     
     
     
     
    3.
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     
     
     
    5.
    SOLE VOTING POWER
     
     
     
     
     
    0
     
     
     
     
    6.
    SHARED VOTING POWER
     
     
     
     
     
    7,007,974 (1)
     
     
     
     
    7.
    SOLE DISPOSITIVE POWER
     
     
     
     
     
    0
     
     
     
     
    8.
    SHARED DISPOSITIVE POWER
     
     
     
     
     
    7,007,974 (1)
     
     
     
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
    7,007,974 (1)
     
     
     
     
    10.
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
     [_]
     
     
     
     
     
     
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
    5.7% (2)
     
     
     
     
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IN, HC
     
     
    (1) Includes 77,500 shares of Common Stock of the Issuer underlying options.
    (2) Based on 123,554,612 shares of Common Stock of the Issuer outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 6, 2024.



    CUSIP No.
    40131M109
     
     

    Item 1.
    (a).
    Name of Issuer:
     
     
     
     
    Guardant Health, Inc. (the "Issuer")
     

     
    (b).
    Address of Issuer's Principal Executive Offices:
     
     
     
     
    3100 Hanover Street
    Palo Alto, California 94304
     

    Item 2.
    (a).
    Name of Person Filing:
     
     
     
     
     
     
     
    Cadian Capital Management, LP
    Cadian Capital Management GP, LLC
    Eric Bannasch
     
    The filing persons named above are collectively referred to herein as the "Reporting Persons."
     

     
    (b).
    Address of Principal Business Office, or if None, Residence:
     
     
     
     
    Cadian Capital Management, LP
    535 Madison Avenue
    36th Floor
    New York, NY 10022
     
    Cadian Capital Management GP, LLC
    535 Madison Avenue
    36th Floor
    New York, NY 10022
     
    Eric Bannasch
    535 Madison Avenue
    36th Floor
    New York, NY 10022
     
     
     
     
     

     
    (c).
    Citizenship:
     
     
     
     
    Cadian Capital Management, LP – Delaware
    Cadian Capital Management GP, LLC – Delaware
    Eric Bannasch – United States of America
     

     
    (d).
    Title of Class of Securities:
     
     
     
     
     
     
     
    Common Stock, par value $0.00001 per share ("Common Stock")
     

     
    (e).
    CUSIP No.:
     
     
     
     
    40131M109
     




    Item 3.
     
    If This Statement is filed pursuant to Rule 13d-1(b) or Rule 13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    [_]
    Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).

     
    (b)
    [_]
    Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     
    (c)
    [_]
    Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

     
    (d)
    [_]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     
    (e)
    [X]
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     
     
    (f)
    [_]
    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     
    (g)
    [X]
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     
    (h)
    [_]
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     
    (i)
    [_]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    [_]
    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     
    (k)
    [_]
    Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

    If filing as a non-US institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:  ______________.
     
    Item 4.
    Ownership.

     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned:
     
     
     
     
     
    Cadian Capital Management, LP – 7,007,974 (1)
    Cadian Capital Management GP, LLC – 7,007,974 (1)
    Eric Bannasch – 7,007,974 (1)

     
    (b)
    Percent of class:
     
     
     
     
     
    Cadian Capital Management, LP – 5.7%
    Cadian Capital Management GP, LLC – 5.7%
    Eric Bannasch – 5.7%
     
    Such percentages are based on 123,554,612 shares of Common Stock outstanding as of November 1, 2024, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024.




     
    (c)
    Number of shares as to which the person has:

     
     
    Cadian Capital Management, LP

     
     
    (i)
    Sole power to vote or to direct the vote
    0
    ,
     
     
     
     
     
     
     
    (ii)
    Shared power to vote or to direct the vote
    7,007,974 (1)
    ,
     
     
     
     
     
     
     
    (iii)
    Sole power to dispose or to direct the disposition of
    0
    ,
     
     
     
     
     
     
     
    (iv)
    Shared power to dispose or to direct the disposition of
    7,007,974 (1)
    .
     
     
     
     
     

     
     
    Cadian Capital Management GP, LLC

     
     
    (i)
    Sole power to vote or to direct the vote
    0
    ,
     
     
     
     
     
     
     
    (ii)
    Shared power to vote or to direct the vote
    7,007,974 (1)
    ,
     
     
     
     
     
     
     
    (iii)
    Sole power to dispose or to direct the disposition of
    0
    ,
     
     
     
     
     
     
     
    (iv)
    Shared power to dispose or to direct the disposition of
    7,007,974 (1)
    .
     
     
     
     
     

     
     
    Eric Bannasch
     
     
     
     
     
    (i)
    Sole power to vote or to direct the vote
    0
    ,
     
     
     
     
     
     
     
    (ii)
    Shared power to vote or to direct the vote
    7,007,974 (1)
    ,
     
     
     
     
     
     
     
    (iii)
    Sole power to dispose or to direct the disposition of
    0
    ,
     
     
     
     
     
     
     
    (iv)
    Shared power to dispose or to direct the disposition of
    7,007,974 (1)
    .

    (1) Includes 77,500 shares of Common Stock of the Issuer underlying options.

    All securities reported in this Schedule 13G are directly held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP (collectively, the "Advisory Clients"), advisory clients of Cadian Capital Management, LP (the "Adviser").  Pursuant to Investment Management Agreements, as amended, between the Advisory Clients and the Adviser, the Adviser exercises exclusive voting and investment power over securities directly held by the Advisory Clients.  Cadian Capital Management GP, LLC is the general partner of the Adviser.  Eric Bannasch is the sole managing member of Cadian Capital Management GP, LLC.
     
    Item 5.
    Ownership of Five Percent or Less of a Class.

     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
     
    N/A

    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.

     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
     
     
    All securities reported in this Schedule 13G are directly held by Advisory Clients. Cadian Master Fund L.P. individually directly holds Common Stock representing more than 5% of the Issuer’s Common Stock.
     
     



    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
     
    The disclosure regarding the relationships among the Reporting Persons in Item 4 is incorporated by reference herein.
     
     

    Item 8.
    Identification and Classification of Members of the Group.
     
     
    If a group has filed this schedule pursuant to Rule 13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
     
     
     
    N/A
     
     

    Item 9.
    Notice of Dissolution of Group.

     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
     
     
    N/A

     
    Item 10.
     
    Certification.

     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     

     
    November 13, 2024
     
    (Date)

     
     
     
    Cadian Capital Management, LP
     
     
    By: Cadian Capital Management GP, LLC, its General Partner
     
     
    By:  /s/ Eric Bannasch
     
    Eric Bannasch
     
    Managing Member
     
     
    Cadian Capital Management GP, LLC 
     
     
    By:  /s/ Eric Bannasch
     
    Eric Bannasch
     
    Managing Member
     
     
     
    /s/  Eric Bannasch
     
    Eric Bannasch


    EXHIBIT INDEX

    99.1
    Joint Filing Agreement, dated as of November 13, 2024, by and among the Reporting Persons
     
     

    Exhibit 99.1
     
    AGREEMENT
     
    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of Schedule 13G (including additional amendments thereto) with respect to the Common Stock, par value $0.00001 per share, of Guardant Health, Inc.  This Joint Filing Agreement shall be filed as an Exhibit to such Statement. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.
     
     Dated:  November 13, 2024

     
     
     
    Cadian Capital Management, LP
     
     
    By: Cadian Capital Management GP, LLC, its General Partner
     
     
    By:  /s/ Eric Bannasch
     
    Eric Bannasch
     
    Managing Member
     
     
    Cadian Capital Management GP, LLC 
     
     
    By:  /s/ Eric Bannasch
     
    Eric Bannasch
     
    Managing Member
     
     
     
    /s/  Eric Bannasch
     
    Eric Bannasch

    Get the next $GH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GH

    DatePrice TargetRatingAnalyst
    9/25/2025$75.00Peer Perform → Outperform
    Wolfe Research
    9/22/2025$72.00Overweight
    Wells Fargo
    4/10/2025$55.00Outperform
    Mizuho
    1/23/2025$60.00Overweight
    Barclays
    6/28/2024$36.00Neutral → Buy
    Guggenheim
    6/3/2024$32.00Buy
    Jefferies
    4/24/2024$28.00Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    More analyst ratings

    $GH
    SEC Filings

    View All

    Guardant Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Guardant Health, Inc. (0001576280) (Filer)

    9/24/25 7:50:17 AM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 144 filed by Guardant Health Inc.

    144 - Guardant Health, Inc. (0001576280) (Subject)

    9/17/25 4:17:32 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Guardant Health, Inc. (0001576280) (Filer)

    9/15/25 4:11:12 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    3/19/24 5:29:06 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

    This marks the second FDA-approved indication for Guardant360 CDx as a companion diagnostic in breast cancer treatment ESR1 mutations are present in 40% of HR+, HER2- advanced breast cancers Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx as a companion diagnostic to identify advanced breast cancer patients with ESR1 mutations who may benefit from Eli Lilly and Company's Inluriyo (imlunestrant). Guardant360 CDx was approved in conjunction with Inluriyo for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-ne

    9/29/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

    Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest's vast network Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant's Shield™ blood-based screening test available to physicians and patients served by Quest in the United States. Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. Through a multi-year agreement, Quest's provider clients that

    9/24/25 8:05:00 AM ET
    $DGX
    $GH
    Medical Specialities
    Health Care

    Alex M. Azar II Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

    9/15/25 4:07:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Azar Alex M Ii

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    9/26/25 5:04:57 PM ET
    $GH
    Medical Specialities
    Health Care

    New insider Azar Alex M Ii claimed no ownership of stock in the company (SEC Form 3)

    3 - Guardant Health, Inc. (0001576280) (Issuer)

    9/26/25 5:03:33 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 27% to 1,083 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    9/18/25 4:33:55 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guardant Health upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Guardant Health from Peer Perform to Outperform and set a new price target of $75.00

    9/25/25 8:22:52 AM ET
    $GH
    Medical Specialities
    Health Care

    Wells Fargo resumed coverage on Guardant Health with a new price target

    Wells Fargo resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $72.00

    9/22/25 8:30:36 AM ET
    $GH
    Medical Specialities
    Health Care

    Mizuho initiated coverage on Guardant Health with a new price target

    Mizuho initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $55.00

    4/10/25 12:41:47 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Financials

    Live finance-specific insights

    View All

    Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $915 to $925 million, representing growth of 24% to 25% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights For the three-month period ended June 30, 2025, as compared to the same period of 2024: Reported total revenue of $232.1 million, an increase of 31%, driven by: Oncology revenue of $158.7 million, an increase of 22%, and approximately 64,000 oncology tests, an increase of 30% Screening revenue of $14.8

    7/30/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012,

    7/14/25 8:00:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25% Screening revenue of $5.7 milli

    4/30/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Leadership Updates

    Live Leadership Updates

    View All

    Alex M. Azar II Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

    9/15/25 4:07:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

    Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

    3/5/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Roberto A. Mignone Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

    10/24/24 5:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/13/24 7:34:17 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/8/24 10:46:38 AM ET
    $GH
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

    SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

    7/5/24 10:32:48 AM ET
    $GH
    Medical Specialities
    Health Care